[Chemotherapy for patients with local-regional recurrent or metastatic carcinoma of the head and neck].
Chemotherapy has emerged to be a central component of curative strategies for patient with primary squamous cell carcinoma of the head and neck. The identification of agent active in head and neck cancer first occurred in patients with local regional recurrent and/or metastatic disease treated with palliative intent. The present paper reports the prognostic factors which based the understanding of these patients outcome. A review of the relevant results obtained by the standard chemotherapy in this recurrent population is performed. The current and future area of research were highlighted.
Dufresne
Armelle
A
Service d'oncologie médicale, CHU J. Minjoz, Besançon cedex.
Gainet
Marie
M
Stein
Ulrich
U
Guardiola
Emmanuel
E
Pivot
Xavier
X
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D000068818:Cetuximab; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D015870:Gene Expression; D016158:Genes, p53 / Q000502:physiology; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D012142:Respiratory Tract Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D066246:ErbB Receptors; D000068818:Cetuximab